These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 20589722

  • 1. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.
    J Cell Biochem; 2010 Aug 01; 110(5):1187-94. PubMed ID: 20589722
    [Abstract] [Full Text] [Related]

  • 2. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z.
    Neoplasma; 2001 Aug 01; 48(5):419-24. PubMed ID: 11845989
    [Abstract] [Full Text] [Related]

  • 3. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 4. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.
    Prostate; 2010 Aug 15; 70(11):1166-78. PubMed ID: 20333699
    [Abstract] [Full Text] [Related]

  • 5. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 6. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.
    Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234
    [Abstract] [Full Text] [Related]

  • 7. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 8. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J, Xie B, Capodice JL, Katz AE.
    Prostate; 2012 Feb 01; 72(3):244-52. PubMed ID: 21656835
    [Abstract] [Full Text] [Related]

  • 9. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M, Neuwirt H, Cavarretta IT, Hobisch A, Culig Z.
    Prostate; 2007 Aug 01; 67(11):1194-201. PubMed ID: 17520660
    [Abstract] [Full Text] [Related]

  • 10. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q, Titus MA, Fung KM, Lin HK.
    J Cell Biochem; 2008 Aug 01; 104(5):1612-24. PubMed ID: 18320593
    [Abstract] [Full Text] [Related]

  • 11. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
    Kawabata R, Oie S, Takahashi M, Kanayama H, Oka T, Itoh K.
    Int J Oncol; 2011 Jun 01; 38(6):1489-500. PubMed ID: 21455575
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells.
    Huang YW, Wang LS, Chang HL, Ye W, Dowd MK, Wan PJ, Lin YC.
    Anticancer Res; 2006 Jun 01; 26(3A):1925-33. PubMed ID: 16827126
    [Abstract] [Full Text] [Related]

  • 14. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE, Chung LW.
    Prostate; 2007 May 15; 67(7):722-31. PubMed ID: 17342749
    [Abstract] [Full Text] [Related]

  • 15. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 16. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 17. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 18. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
    Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP, Sarkar FH.
    Int J Oncol; 2003 Apr 01; 22(4):787-94. PubMed ID: 12632069
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.